Pancreatic Cancer Research

ResearcherChangzhou No.2 People's HospitalNo recent work listed

Liming Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3730-3131; OpenAlex author ID A5025488784. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 4

  1. LEM domain containing 1 promotes pancreatic cancer growth and metastasis by p53 and mTORC1 signaling pathway. Last author DOI 10.1080/21655979.2022.2047404↗
  2. MUC4 is a novel mediator in H. pylori infection-related pancreatic cancer. Last author DOI 10.3892/ol.2020.12384↗
  3. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway. Last author DOI 10.1002/jcp.29181↗
  4. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway. Co-author DOI 10.1002/mc.23011↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yue Fu · 4 shared papers, 2019–2022 · strength 0.54
  2. Na Yao · 3 shared papers, 2019–2022 · strength 0.40
  3. Xiang Cao · 1 shared paper, 2022 · strength 0.16
  4. Yu Long Gong · 1 shared paper, 2021 · strength 0.14
  5. Qiuyang Chen · 1 shared paper, 2019 · strength 0.12
  6. Chunfu Zhu · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.